Milestone Pharmaceuticals Inc. (MIST)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Milestone Pharmaceuticals: Reiterating Sell As The Losses Compound
Milestone Pharmaceuticals remains a 'Sell' due to weak CARDAMYST differentiation and poor commercial uptake versus low-cost generics. MIST's Q2 revenue was just $559K on over 1,200 scripts, reflecting heavy discounting and minimal payer coverage, with only ~20% of the PSVT market covered. Financial health is deteriorating: $170M cash, $39M 1H burn, liabilities doubled to $163M, and equity fell to $18M amid high SG&A and compounding royalty debt.
Milestone Pharmaceuticals Inc. (MIST) Q2 2026 Earnings Call Transcript
Milestone Pharmaceuticals Inc. (MIST) Q2 2026 Earnings Call Transcript
Milestone Pharmaceuticals Q2 Earnings Call Highlights
Milestone Pharmaceuticals NASDAQ: MIST reported early commercial traction for CARDAMYST following its mid-February launch, while advancing a pivotal Phase III study of etripamil in atrial fibrillation with rapid ventricular rate, or AFib-RVR.
Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates
Milestone Pharmaceuticals (MIST) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.2 per share a year ago.
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Milestone Pharmaceuticals (MIST)
Milestone Pharmaceuticals (MIST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Milestone Pharmaceuticals: Here Comes The Revenue Ramp
Milestone Pharmaceuticals Inc. remains a Strong Buy, despite recent volatility and a 37% stock decline since FDA approval of Cardamyst. Cardamyst's rapid-acting efficacy, expanding insurance coverage, and unique market position underpin a compelling medium-term ramp in prescriptions and revenue. International expansion and a Phase 3 trial for AFib-RVR could significantly enlarge MIST's addressable market and long-term growth prospects.
Milestone Pharmaceuticals Q1 Earnings Call Highlights
Milestone Pharmaceuticals NASDAQ: MIST said its first quarter of 2026 marked the beginning of commercial sales for CARDEMYST, its newly approved treatment for acute episodes of paroxysmal supraventricular tachycardia, or PSVT, while the company also moved ahead with a Phase 3 program in atrial fibrillation with rapid ventricular rate.
Milestone Pharmaceuticals Inc. (MIST) Q1 2026 Earnings Call Transcript
Milestone Pharmaceuticals Inc. (MIST) Q1 2026 Earnings Call Transcript
Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue Estimates
Milestone Pharmaceuticals (MIST) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of $0.06. This compares to a loss of $0.31 per share a year ago.
Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call Transcript
Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call Transcript
All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy
Milestone Pharmaceuticals (MIST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense
Milestone Pharmaceuticals Inc. receives a Strong Buy rating, driven by Cardamyst's FDA approval and imminent commercial launch for PSVT. MIST's Cardamyst demonstrated rapid efficacy, favorable safety, and potential to reduce costly emergency visits, supporting robust market adoption. With over $150 million in cash, minimal near-term dilution risk, and nearly $1 net cash per share, MIST offers a highly asymmetric risk-reward.
